VBIO

Valion Bio, Inc. VBIO

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.8M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-7.10M

Quarter to Jun 30

Free cash flow

$-5.34M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$205.6K total
Murchinson Ltd.
$59.8KNew
CITADEL ADVISORS LLC
$38.5KNew
Sanctuary Advisors, LLC
$31.8K0.0%
Marex Group plc
$28.2K-8.4%
Virtu Financial LLC
$20.0KNew
GEODE CAPITAL MANAGEMENT, LLC
$10.1K-77.9%
UBS Group AG
$5.8K+368.9%
TWO SIGMA SECURITIES, LLC
$5.3KNew
HRT FINANCIAL LP
$5.0K-73.0%
Tower Research Capital LLC (TRC)
$1.1K+258.7%
SBI Securities Co., Ltd.
$80.0%
TD Waterhouse Canada Inc.
$2New
Caitong International Asset Management Co., Ltd
$10.0%
See all 13 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/VBIO

Earnings Per Share

13fpro.ai/company/VBIO

Loading ratio trend…

VBIO key financials by period

Reported revenue, net income and operating margin by fiscal year, from Valion Bio, Inc.'s annual filings on SEC EDGAR.

Valion Bio, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$780.0K$-5.7M—
FY 2023$1.2M$-8.2M—
FY 2022$1.8M$-10.1M—
FY 2021$1.3M$-8.5M—
Source: VBIO filings on SEC EDGAR →

VBIO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Valion Bio, Inc. (VBIO): stock profile, AI score and financials

Valion Bio, Inc. (VBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VBIO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.8m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Valion Bio, Inc. reports net income of $-7.1M, free cash flow of $-5.3M. Top institutional holders of VBIO by reported 13-F value include Murchinson Ltd., CITADEL ADVISORS, Sanctuary Advisors, based on the most recent SEC filings. VBIO trades on the Nasdaq exchange and files with the SEC under CIK 1787740. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Valion Bio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1787740 →